Wire · regulatory
FDA recognizes standalone software's role in improving drug therapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
The U.S. FDA has finalized guidance establishing a clear regulatory pathway for standalone software related to prescription drugs, including dosage reminders and device-connected apps. The guidance mandates labeling for essential apps and supports broader use cases with a risk-based framework, enhancing digital health integration in drug therapy.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
The FDA's clear rules on prescription drug software open a trusted route for you to build and distribute apps that improve medication use. Getting aligned with FDA's labelling and evidence requirements this week sharpens your chances to enter or expand in pharma-adjacent digital health.
◆ Coverage
1 source · 22 Oct 2026
◆ Related on Wire
◆ Topics